SOURCE: BioMedReports


November 07, 2011 08:52 ET

Exclusive: President and CEO of IntelGenX Discusses the Firm's Pending FDA Decision

LOS ANGELES, CA--(Marketwire - Nov 7, 2011) - In an exclusive interview, Horst G. Zerbe, Ph.D., President and CEO of IntelGenX Corporation (OTCBB: IGXT) shares his thoughts on the firm's pending U.S. regulatory decision involving the drug candidate CPI-300.

CPI-300 is also known as INT0004, IntelGenX's new strength antidepressant bupropion hydrochloride -- an oral antidepressant drug of the aminoketone class which selectively inhibits the neuronal reuptake of dopamine, norepinephrine, and serotonin.

Some observers believe that while a CPI-300 approval can become a financial win for the company it may also prove to be a key symbolic victory; one showing that IntelGenX can develop a product from the bench through approval.

The full exclusive interview, including some of the catalysts investors should be looking for in 2012 as far as IntelGenX is concerned, is available now at:

In addition, investors interested in accessing BioMedReports' new complete database of clinical trials and upcoming FDA and world-wide regulatory decisions which can be used to make more profitable trades during these volatile markets can go to:

News developments and live healthcare sector updates are available constantly via twitter at:

About BioMedReports.Com

BioMedReports is a news portal covering the biomedical news and financial sector. BioMedReports is not paid or compensated to report the news and developments of publicly traded companies in the healthcare sector of the markets. Full disclosures and information about these stocks and news are available at BioMedReports.Com

Contact Information

  • Media Contacts Only:
    Mary Davila
    Assistant Editor
    e-mail: Email Contact
    Tel: +1 323 472 4480
    Fax: +1 888 210 3556